This is a preview of subscription content, log in via an institution to check access.
Notes
Both studies were affiliated with Ipsen Global or Ipsen Pharma.
References
1. Danchenko N, et al. Cost-Effectiveness of BoNT-A Products for Treatment of Pediatric Spasticity in the United Kingdom. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND37, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/111208
2. Johnston K, et al. BoNT-As for Adult Spasticity and Cervical Dystonia- Cost-Effectiveness Analysis and the Cost of Response in the United Kingdom. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND18, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/111171
Rights and permissions
About this article
Cite this article
Abobotulinumtoxin-A may be a cost-effective choice for managing spasticity in the UK. PharmacoEcon Outcomes News 880, 1 (2021). https://doi.org/10.1007/s40274-021-7759-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7759-z